A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. BOSTON, July 11th, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class Read more

Boston-based fast-growing radiopharmaceutical company opens the doors to its new headquarters and research facility to advance targeted radiotherapies for cancer BOSTON, May 9, 2023 – Ratio Therapeutics Inc., a pharmaceutical company focused on developing innovative radiopharmaceuticals for the treatment of cancer, is pleased Read more

Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications BOSTON, March 28, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment Read more

BOSTON, March 13, 2023 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, today announced the appointment of Dr. Noel Monks as the company’s Head of Biology. Dr. Monks joins Ratio with over 20 years Read more

Boston-Based Pharmaceutical Company Brings Total Financing to More Than $40 Million since 2022 Launch Dr. Susan K. Whoriskey, Ph.D., to Join the Company’s Board of Directors as Strategic Advisor BOSTON, February 1, 2023 – Ratio Therapeutics Inc., a pharmaceutical company specializing in the Read more

BOSTON, December 6, 2022 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Reed Malleck as the company’s Chief Financial Officer (CFO). Read more